Latest news for Elders (OTC:EDRSF) Stock

Elders Ltd is a farm products company. The company's operating segments include Branch Network; Wholesale Products; Feed and Processing Services and Corporate Services and Other Costs. It generates maximum revenue from the Branch Network segment. The Branch Network segment includes the provision of products and services through a common distribution channel, including agricultural retail products, agency services, and financial services. Geographically earns revenue from Australia itself, from maximum in retail products.

Elders Ltd

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) with a Buy and maintains $7.25 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Endeavour Silver, Maintains $7.25 Price Target

WIIM

Core & Main shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

The reverse split was approved by the Company's shareholders on November 25, 2024 and will be effective as of the commencement of trading on December 5, 2024. The reverse stock split is being implemented for the purpose of complying with the closing bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

AGRI

AgriFORCE To Implement 100-For-1 Reverse Stock Split For Nasdaq Compliance

The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels. These findings were supported by significantly improved Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values, a standard measure used to assess insulin sensitivity and resistance.

Biotech

Health Care

General

TELO

Telomir Pharmaceuticals Announced Preclinical Results Confirming The Efficacy Of Its Licensed Molecule Telomir-1 In Reversing Several Key Parameters Of Type 2 Diabetes Mellitus

<ul>
<li>In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>

ARWR

Arrowhead Pharmaceuticals Has Filed A Request For Regulatory Clearance To Initiate A Phase 1/2a Trial Of ARO-ALK7 As A Potential Treatment For Obesity

Keefe, Bruyette &amp; Woods analyst David Konrad maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Market Perform and raises the price target from $216 to $254.

Keefe, Bruyette & Woods Maintains Market Perform on JPMorgan Chase, Raises Price Target to $254

Buybacks

Cheer Holding Approves $50M Share Buyback Program Over the Next Three Years

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) with a Buy and maintains $15 price target.

BCTX

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $15 Price Target

On Tuesday, Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) announced that it has achieved breakthroughs in catalyzing graphitization to produce high-quality synthetic graphite with its patented green graphite production technology.&nbsp;&nbsp;
The company said its green graphite technology is the first in the world to produce artificial graphite directly from palm kernel shells, a widely available waste product in Malaysia and Indonesia.
Pilot-scale testing has demonstrated that Graphjet&#8217;s artificial graphite can achieve up to 99.99% purity levels.&nbsp;&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides" rel="noreferrer noopener">Biden Targets China With New Chip Restrictions, Nvidia Slides</a>
In addition to the high purity levels achieved, Graphjet&#8217;s production technology boasts a 98.8% graphitization level.
The artificial graphite production process generally involves raw material mixing, molding, high-temperature and high-pressure graphitization, and modification of graphite characteristics.
A high graphitization level is key for the company&#8217;s green graphite technology. High graphitization demonstrates that the composition of the graphite lattice is highly organized and of a uniform crystal structure, which results in improved physical and chemical characteristics.
The company said graphite of this quality is a remarkable material for industries and applications such as lithium-ion batteries, thermal management, and graphite electrodes.&nbsp;&nbsp;
Third-party labs in China have validated the company&#8217;s technological achievements, the company said.
Higher graphitization levels signify a higher percentage of graphite crystal formation within a graphite sample. The graphitization level will depend on critical factors such as temperature, pressure, time, and graphitization gas.&nbsp;&nbsp;
Artificial graphite with favorable heat conductivity, stability, and chemical properties can be used to produce lithium-ion batteries, graphite electrodes, heat management, and high-performance porcelain industries.
The company said that Graphjet&#8217;s high-performance artificial graphite will enable the market to foster breakthrough technologies and new applications, thereby extending the range of applications.&nbsp;&nbsp;
Graphjet recently commissioned the world&#8217;s first and largest green graphite facility in Malaysia. The facility has an annual production capacity of up to 3,000 metric tons of battery-grade graphite. This production level supports battery production for approximately 40,000 electric vehicles annually.
The company said that per kg of graphite produced, Graphjet&#8217;s patented technology produces only 2.95 kg of CO2 emissions, compared to 16.8 kg and 17 kg from natural and synthetic graphite production in China.
Price Action: GTI stock closed lower by 6.69% at $2.51 on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42265010/amazon-and-walmart-dominate-black-friday-as-online-sales-soar-146" target="_blank" rel="noreferrer noopener">Amazon And Walmart Dominate Black Friday As Online Sales Soar 14.6%</a></li>
</ul>

Commodities

Market-Moving Exclusives

Exclusives

EXCLUSIVE: Graphjet Technology Pilot Testing Accomplishes 99.99% Graphite Purity And 98.8% Graphitization

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), a leading beverage alcohol company, today announced that it has reached an agreement with global spirits company Sazerac, to divest its SVEDKA brand. This transaction is expected to close in the coming months.
The decision builds on the company's strategic efforts to further align the wine and spirits portfolio with evolving consumer preferences and growing market sectors, focusing on higher end wine and spirits brands and products. Over the last few years, Constellation has divested the majority of its popular and mainstream wine and spirits brands within the portfolio and is focused on competing predominantly in premium and fine wine and craft spirits segments.

Constellation Brands To Divest SVEDKA, Strengthens Focus On Premium Wine And Craft Spirits

EXCLUSIVE: Graphjet Tells Benzinga 'Achieved 99.99% graphite purity and 98.8% graphitization, two key milestones further validating the quality of Graphjet Technology's technology and its viability at scale'

EXCLUSIVE: Graphjet Tells Benzinga Co. Achieves Technological Breakthroughs With Green Graphite Production

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.00%</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $55 to $60 on Nov. 12. This analyst has an accuracy rate of 72%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $73 on Nov. 12. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: Bristol-Myers Squibb filed a lawsuit last week against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA&#8217;s rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png" alt="" class="wp-image-674099" style="width:737px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15-768x713.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.61%</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Geoff Meacham maintained a Buy rating and cut the price target from $226 to $215 on Nov. 12. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 18, AbbVie secured European Commission approval for ELAHERE, first novel therapy for platinum-resistant ovarian cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"> latest ABBV new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png" alt="" class="wp-image-674101" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043214/image-16-768x708.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 4.75%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 80%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and lowered the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Patterson Companies will hold its fiscal 2025 second-quarter conference call on Thursday, Dec. 5.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">PDCO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png" alt="" class="wp-image-674102" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043251/image-17-768x705.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42267284/this-analyst-with-85-accuracy-rate-sees-more-than-8-upside-in-crowdstrike-here-are-5-stock-picks-for-november-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In CrowdStrike &#8211; Here Are 5 Stock Picks For November From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ABBV

PDCO

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Outperform and raises the price target from $570 to $686.

Keefe, Bruyette & Woods Maintains Outperform on Goldman Sachs Gr, Raises Price Target to $686

The two companies will collaborate on camera design, features, testing and manufacturing, initially for a 25-megapixel camera to be used in the ZenaDrone IQ Series of indoor/outdoor drones. The first camera for the IQ Nano drone is expected to be ready to ship in a matter of weeks. This will be followed by collaboration on NDAA-compliant AI drone cameras to be incorporated into ZenaDrone 1000 drones designed for defense organizations for surveillance, reconnaissance, logistics and tactical missions.

ZENA

ZenaTech Partners With Suntek Global To Develop Blue UAS And NDAA-Compliant AI Drone Cameras For US Defense

"We are raising our full year outlook based on results to-date, recent acquisitions, and our expectation that both prices and our end markets will remain stable through the end of the year," LeClair said. "The non-discretionary repair and replacement portion of our business remains resilient, and we are pleased with our level of execution to expand gross margins sequentially from the second quarter. We expect full year net sales to range from $7,350 to $7,450 million and we expect Adjusted EBITDA to range from $915 to $935 million. Our teams continue to lead and innovate, and we are optimistic that our scale, entrepreneurial culture and strong balance sheet position us to deliver meaningful value creation over the long-term."

Earnings

Guidance

Core & Main Expects Full Year 2024 Net Sales Of $7.35B-$7.45B, Versus Consensus Of $7.357B, With Adjusted EBITDA Of $915M-$935M

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and raises the price target from $117 to $123.

XOMA

HC Wainwright & Co. Maintains Buy on XOMA Royalty, Raises Price Target to $123

CYTK

Cytokinetics Launches Phase 3 COMET-HF Trial For Omecamtiv Mecarbil In Severe Heart Failure Patients

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Outperform and raises the price target from $87 to $96.

Keefe, Bruyette & Woods Maintains Outperform on Bank of New York Mellon, Raises Price Target to $96

REX American Resources Reported Q3 Consolidated Ethanol Sales Volumes Of 75.5M Gallons, An Increase Of Approximately 3% Compared To The Same Period In Fiscal 2023

Comments

Elders

News

Latest news for Elders (OTC:EDRSF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga